Mucopolysaccharidosis patients and families
Having listened to the agonizing cries of patients and their families suffering from the rare disease mucopolysaccharidosis (MPS), and truly understanding their needs, the MPS patient care team at Mackay Memorial Hospital has, for nearly 20 years, focused on providing the most practical and enhanced medical care. This has been combined with domestic and international professional research capabilities and resources to address the urgent needs of patients and their families one by one. The team also actively participates in international academic research activities aimed at improving diagnostic and treatment processes and enhancing efficacy. Providing holistic care and support for MPS patients and their families is the team's profession, responsibility, and mission.
No.1 in the world:
First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.
First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.
First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.
No.1 in the world:
The world's earliest and largest newborn screening test for mucopolysaccharidosis types 1, 2, 6, and 4A (pilot study started in 2008, comprehensive newborn screening started in 2015, and more than 850,000 cases have been screened so far) (European, American and Japanese countries: small-scale newborn screening began in 2018, currently less than 100,000 persons have been screened)
The world's largest: Mucopolysaccharidosis newborn screening "gene variation" and "genotype-phenotype correlation" database (Europe, the United States and Japan: None)
No.1 in the world:
First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.
First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.
First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.
The overall satisfaction rate of care services for patients with rare diseases is 96.4% in 2025.
The overall satisfaction rate of care services for patients with rare diseases is 96.4% in 2025.
No.1 in the world:
First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.
First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.
First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.
No.1 in the world:
First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.
First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.
First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.
